Status:
COMPLETED
Ancillary Study GOG 158: Survival Analysis Based on Reclassification to a Two-Tier Grading System
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborating Sponsors:
Gynecologic Oncology Group
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
Brief Summary
Primary Objective: * To reclassify the histologic grade of the serous ovarian cancer specimens of patients enrolled on Gynecologic Oncology Group (GOG) protocol 158 using a two-tier system. Secondar...
Detailed Description
The purpose of this study is to describe the progression-free and overall survival of patients treated on GOG protocol 158 when their tumors are reclassified into a two-tier grading system. Although n...
Eligibility Criteria
Inclusion
- All patients enrolled on GOG protocol 158 with a diagnosis of serous carcinoma of the ovary.
Exclusion
- None
Key Trial Info
Start Date :
August 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
241 Patients enrolled
Trial Details
Trial ID
NCT00837993
Start Date
August 1 2007
End Date
December 1 2012
Last Update
December 21 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030